Medicine and Clinical Science

Monitoring Viral Suppression when switching from fixed dose combination efavirenz, emtricitabine and tenofovir (Atripla) to fixed dose combination elvitegravir, cobicistat, emtricitabine, and tenofovir (Stribild) in virologically suppressed adults with HIV

Edward W. Braun
  10.33425/2690-5191.1015 Published: 30 Dec, 2019
Braun WE. Monitoring Viral Suppression when switching from fixed dose combination efavirenz, emtricitabine and tenofovir (Atripla) to fixed dose combination elvitegravir, cobicistat, emtricitabine, and tenofovir (Stribild) in virologically suppressed adults with HIV. Med Clin Sci. 2020;2(1):1-5.
Download Citation Abstract PDF